Novartis AG ADR (NVS)vsArcus Biosciences Inc (RCUS)
NVS
Novartis AG ADR
$146.57
-0.87%
HEALTHCARE · Cap: $282.11B
RCUS
Arcus Biosciences Inc
$25.68
+0.71%
HEALTHCARE · Cap: $3.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 22806% more annual revenue ($56.58B vs $247.00M). NVS leads profitability with a 23.9% profit margin vs -142.9%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
RCUS
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$146.57
$36.97 premium
Margin of Safety
+88.4%
Fair Value
$183.65
Current Price
$25.68
$157.97 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Conservative balance sheet, low leverage
Revenue surging 26.9% year-over-year
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Weak financial health signals
ROE of -63.3% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : RCUS
The strongest argument for RCUS centers on Debt/Equity, Revenue Growth. Revenue growth of 26.9% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : RCUS
The primary concerns for RCUS are EPS Growth, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while RCUS is a growth play — different risk/reward profiles.
RCUS carries more volatility with a beta of 0.86 — expect wider price swings.
RCUS is growing revenue faster at 26.9% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 30/100), backed by strong 23.9% margins. RCUS offers better value entry with a 88.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Arcus Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?